Physician profile
Brian C Johnson
NPI 1609308717
$818.84
in general payments reported to CMS, 2019-2025
21 companies · $94.35 in 2025
The $94.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.42 · 2021: $257 · 2022: $138 · 2023: $99.18 · 2024: $180 · 2025: $94.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.15 | 2021-2025 | |
| Pfizer INC. | $64.93 | 2023-2025 | |
| Medtronic, INC. | $61.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.40 | 2021-2024 | Synjardy, Jardiance |
| Novo Nordisk INC | $41.34 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $36.01 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $33.61 | 2021-2024 | Airsupra |
| Boston Scientific Corporation | $32.96 | 2022-2025 | Watchman Flx |
| Inspire Medical Systems, INC. | $28.99 | 2025 | Inspire |
| Allergan, INC. | $20.49 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.07 | 2023 | Spravato |
| Optinose US, INC. | $19.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.56 | 2022 | |
| Amgen INC. | $16.29 | 2024 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $15.75 | 2023 | Arexvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $15.38 | 2022 | |
| Dexcom, INC. | $14.49 | 2021 | |
| Mylan Specialty L.P. | $14.16 | 2023 | Yupelri |
| Inogen, INC. | $13.24 | 2021 | |
| Eisai INC. | $11.64 | 2021 | |
| Merck Sharp & Dohme LLC | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.